Latest / Mind & Medicine: Neuro Pharma Insights / Aripiprazole The Antipsychotic Every Neuro Franchise Partner Should Know

Transcript

Aripiprazole The Antipsychotic Every Neuro Franchise Partner Should Know · Mind & Medicine: Neuro Pharma Insights

• 0:00
  Speaker 1: One of the most lucrative, like fast growing business monopolies
• 0:03
  Speaker 1: in India right now, isn't built on you know, towering
• 0:07
  Speaker 1: skyscrapers or vast real estate portfolios. It's not some massive
• 0:12
  Speaker 1: digital network either.
• 0:13
  Speaker 2: It's actually much smaller than that.
• 0:15
  Speaker 1: Exactly, it is built on a pill, specifically a pill
• 0:18
  Speaker 1: that is engineered to disappear before a patient can even
• 0:21
  Speaker 1: spit it out. So today we're opening up a really
• 0:25
  Speaker 1: fascinating stack of sources. We've got pharmaceutical market reports, business
• 0:29
  Speaker 1: franchise breakdowns, and clinical psychiatric notes.
• 0:32
  Speaker 2: And now the goal is to uncover how a microscopic
• 0:34
  Speaker 2: chemical tweak is driving a nationwide economic boom.
• 0:38
  Speaker 1: Yeah, we're looking at the Indian neuropharma franchise market.
• 0:41
  Speaker 2: Which is just a remarkably unique sector. I mean, if
• 0:43
  Speaker 2: you want to understand scale and healthcare industry, you often
• 0:47
  Speaker 2: have to invert your perspective, so to speak.
• 0:50
  Speaker 1: We get smaller.
• 0:50
  Speaker 2: Yeah, exactly, you don't look at the masses shipping logistics first.
• 0:53
  Speaker 2: You zoom all the way into the molecular level. Because
• 0:56
  Speaker 2: a whole foundational architecture of these sprawling business opportunities it's
• 1:00
  Speaker 2: entirely on how one specific chemical interacts with the human brain, and.
• 1:05
  Speaker 1: We are zooming in on a very specific business model
• 1:08
  Speaker 1: today that just keeps popping up in these market reports.
• 1:11
  Speaker 1: It's referred to as the PCD franchise model, and the
• 1:15
  Speaker 1: documents say PCD stands for propagandacum.
• 1:19
  Speaker 2: Distribution, which always gets a reaction.
• 1:22
  Speaker 1: I mean, yeah, I have to stop right here because
• 1:24
  Speaker 1: to a Western ear that sounds incredibly intense, like it
• 1:28
  Speaker 1: sounds like some dystopian si off. What does that actually
• 1:31
  Speaker 1: mean in practice?
• 1:32
  Speaker 2: Yeah? No, it catches everyone off guard the first time
• 1:35
  Speaker 2: they see it. It sounds alarming, but it is actually
• 1:38
  Speaker 2: a very standard historic industry phrasing in the Indian business sector.
• 1:42
  Speaker 1: Oh okay, so it's not as scary as it sounds,
• 1:45
  Speaker 1: not at all.
• 1:45
  Speaker 2: The word come is just being used in the traditional
• 1:48
  Speaker 2: Latin sense I meaning with or alongside.
• 1:50
  Speaker 1: Oh right, like graduating cumloudy precisely.
• 1:53
  Speaker 2: So it simply translates to marketing coupled with distribution, got it. Yeah.
• 1:57
  Speaker 2: So in this model, a parent pharmaceutical company manufactures a
• 2:00
  Speaker 2: drug and they grant a local franchise partner the exclusive
• 2:04
  Speaker 2: rights to market and distribute that specific brand in their
• 2:07
  Speaker 2: geographic territory.
• 2:08
  Speaker 1: Okay, well that makes so much more sense. We're basically
• 2:11
  Speaker 1: just talking about exclusive marketing and distribution franchises exactly. And
• 2:15
  Speaker 1: to understand why this market is exploding, our sources point
• 2:18
  Speaker 1: us toward one highly specific molecule that's serving as the
• 2:22
  Speaker 1: cornerstone of these business portfolios. The molecule is aripiprazole. So, okay,
• 2:29
  Speaker 1: let's unpack this because we are transitioning from this massive
• 2:32
  Speaker 1: macro concept of nationwide pharma franchises straight down into the
• 2:37
  Speaker 1: microscopic science, Like what is arapiprosole and why is this
• 2:42
  Speaker 1: one single drug holding up an entire commercial empire?
• 2:45
  Speaker 2: Right? So, ara pitprosole is classified as an atypical antipsychotic.
• 2:49
  Speaker 2: In the clinical psychiatric world. It is primarily prescribed for
• 2:53
  Speaker 2: managing conditions like schizophrenia and bipolar disorder.
• 2:55
  Speaker 1: And it's used for depression too, right, Yeah.
• 2:57
  Speaker 2: It is frequently utilized as an ad on therapy for
• 3:00
  Speaker 2: treating major depressive disorder. But its commercial dominance isn't just
• 3:03
  Speaker 2: about the diseases it treats. It's about its mechanism of action.
• 3:07
  Speaker 1: How it actually works in the brain exactly.
• 3:10
  Speaker 2: You have to look at what it physically does inside
• 3:12
  Speaker 2: the brain compared to the older traditional treatments that.
• 3:15
  Speaker 1: Came before it, Right, because looking at the clinical notes,
• 3:18
  Speaker 1: those older treatments, the traditional antipsychotics, they essentially acted like
• 3:21
  Speaker 1: a sledgehammer like the goal was simply to block dopamine
• 3:25
  Speaker 1: receptors completely, right, Yeah, that.
• 3:27
  Speaker 2: Was the prevailing pharmacological logic for a really long time.
• 3:30
  Speaker 2: The older generation of drugs relied on blunt force dopamine blockade.
• 3:35
  Speaker 1: Just shut it all down pretty much.
• 3:38
  Speaker 2: Because schizophrenia and bipolar mania are often associated with an
• 3:42
  Speaker 2: excess of dopamine activity in certain pathways of the brain.
• 3:45
  Speaker 1: So too much dopamine is causing the issues.
• 3:47
  Speaker 2: Right, So the old solution was straightforward shut those receptors
• 3:51
  Speaker 2: down entirely to suppress the activity across the board.
• 3:54
  Speaker 1: But er pippersol doesn't do that.
• 3:56
  Speaker 2: No, it operates on a completely different philosophy. It is
• 3:59
  Speaker 2: what chemists call a partial agonist.
• 4:02
  Speaker 1: A partial agonist meaning it doesn't just like board up
• 4:05
  Speaker 1: the doors and windows of the dopamine receptors and walk
• 4:08
  Speaker 1: away exactly.
• 4:09
  Speaker 2: What's fascinating here is that it acts more like a thermostat.
• 4:13
  Speaker 1: Oh, a thermostat ok.
• 4:14
  Speaker 2: Yeah, Instead of simply blocking the receptors completely, it modulates
• 4:20
  Speaker 2: the dopamine activity modulates it. Right, So if the dopamine
• 4:23
  Speaker 2: level in a certain pathway is running way too high,
• 4:26
  Speaker 2: the partial agnist suppresses it. But if the dopamine level
• 4:30
  Speaker 2: is actually too low in another area, it actually stimulates
• 4:34
  Speaker 2: it slightly.
• 4:34
  Speaker 1: Oh wow, So it balances it out.
• 4:36
  Speaker 2: Yes, it doesn't entirely shut down the brain's dopamine pathways. Yeah,
• 4:41
  Speaker 2: and that chemical subtlety. It fundamentally changes the patient's lived
• 4:45
  Speaker 2: experience because.
• 4:45
  Speaker 1: They aren't totally depleted of dopamine.
• 4:48
  Speaker 2: Right. Because you aren't completely suppressing dopamine everywhere, the patient
• 4:51
  Speaker 2: sees vastly better tolerability. You avoid many of the severe
• 4:55
  Speaker 2: life altering side effects that are practically guaranteed with those
• 4:58
  Speaker 2: traditional dopamine blocks.
• 5:00
  Speaker 1: Okay, I want to make sure you, the listener, really
• 5:03
  Speaker 1: grasp this concept, because it honestly feels like the key
• 5:06
  Speaker 1: to everything else we are going to explore today. Think
• 5:09
  Speaker 1: about it this way. Imagine you have a house with
• 5:11
  Speaker 1: a badly leaking faucet in the kitchen sink. Okay, I
• 5:13
  Speaker 1: like this, So the traditional antipsychotic approach, the total dopamine blocker,
• 5:19
  Speaker 1: is like going down to the basement and completely shutting
• 5:21
  Speaker 1: off the main water valve to the entire house.
• 5:24
  Speaker 2: Right, which means you absolutely stop the leak in the
• 5:27
  Speaker 2: kitchen sink.
• 5:28
  Speaker 1: Sure, yeah, the immediate crisis is handled. But now you
• 5:31
  Speaker 1: can't take a shower, you can't run the dishwasher, you
• 5:34
  Speaker 1: can't flush the toilet.
• 5:35
  Speaker 2: You fix the sink, but ruin the house exactly.
• 5:37
  Speaker 1: You've ruined the basic livability of the house just to
• 5:40
  Speaker 1: fix one symptom. And in the psychiatric world, ruining the
• 5:44
  Speaker 1: liveability of the house looks like heavy debilitating sedation where
• 5:48
  Speaker 1: a patient can barely stay awake, or.
• 5:50
  Speaker 2: Massive uncontrollable weight gain or rigid muscle treummers.
• 5:54
  Speaker 1: Right. But arapipper zol acting as a partial agonist is
• 5:58
  Speaker 1: more like installing a highly sensitive smart valve directly under
• 6:02
  Speaker 1: that specific kitchen sync.
• 6:04
  Speaker 2: The targeted fix.
• 6:05
  Speaker 1: Yeah, it modulates the water pressure perfectly right where the
• 6:08
  Speaker 1: problem is. It keeps the water flowing but controlled, without
• 6:12
  Speaker 1: disrupting the plumbing for the rest of the house. Yeah, Like,
• 6:14
  Speaker 1: you still get to live your life. You weren't wanting
• 6:16
  Speaker 1: around like.
• 6:16
  Speaker 2: A zombie and preserving that patient's quality of life is
• 6:20
  Speaker 2: exactly why this chemical shift matters so much on a
• 6:23
  Speaker 2: commercial scale.
• 6:24
  Speaker 1: Right, it's not just good medicine.
• 6:25
  Speaker 2: No, that reduction in severe side effects isn't just a
• 6:29
  Speaker 2: nice biological bonus or some marketing talking point. It actually
• 6:33
  Speaker 2: solves the single biggest, most persistent hurdle in all of medicine,
• 6:38
  Speaker 2: which is what well, particularly in mental health treatment, it's compliance.
• 6:43
  Speaker 1: Oh, getting people to actually swallow their medicine day after
• 6:46
  Speaker 1: day exactly.
• 6:47
  Speaker 2: Compliance is quite literally everything.
• 6:49
  Speaker 1: Because if they don't take it, it doesn't matter how
• 6:52
  Speaker 1: good it is.
• 6:52
  Speaker 2: Right, the most perfectly engineered molecule in the world, backed
• 6:56
  Speaker 2: by billions of dollars in research, is clinically useless if
• 6:59
  Speaker 2: the patient just refuses to take it.
• 7:01
  Speaker 1: Yeah, and if you've ever tried to give medication to
• 7:03
  Speaker 1: a stubborn pet, or like tried to convince a toddler
• 7:06
  Speaker 1: to take a spoonful of cough syrup, you know the
• 7:09
  Speaker 1: exact biological friction we're talking about here. Absolutely Now multiply
• 7:12
  Speaker 1: that baseline humans stubbornness by the complexities of a severe
• 7:16
  Speaker 1: mental health condition.
• 7:17
  Speaker 2: It's a huge challenge the sources outline of very stark
• 7:21
  Speaker 2: reality in psychiatric care. It's a very binary outcome in practice.
• 7:26
  Speaker 2: How do you mean, well, if a patient tolerates their medication,
• 7:30
  Speaker 2: meaning they can still function, they are sleeping fourteen hours
• 7:34
  Speaker 2: a day, they aren't gaining massive amounts of weight. They
• 7:37
  Speaker 2: tend to stay on the medication. That makes sense, but
• 7:39
  Speaker 2: when patients experience those heavy side effects from older drugs,
• 7:43
  Speaker 2: they usually make irrational, albeit dangerous calculation.
• 7:47
  Speaker 1: They decided the side effects are worse than the disease itself.
• 7:50
  Speaker 2: Exactly, They decide that the cure is worse than the disease,
• 7:53
  Speaker 2: and they stop taking it.
• 7:54
  Speaker 1: And when they stop taking it, the symptoms return, the
• 7:57
  Speaker 1: condition destabilizes, and the doctor is forced to intervene in right.
• 8:01
  Speaker 2: The psychiatrist then has to switch them to a different
• 8:04
  Speaker 2: brand or a different drug entirely to try and find
• 8:07
  Speaker 2: something the patient will actually tolerate.
• 8:08
  Speaker 1: Wait, so is the commercial success of a psychiatric drug
• 8:12
  Speaker 1: sometimes just as much about how little it annoys or
• 8:15
  Speaker 1: disrupts the patient's daily life, rather than just how powerfully
• 8:19
  Speaker 1: it targets the disease.
• 8:21
  Speaker 2: In many ways, yes, efficacy, how well it targets the
• 8:25
  Speaker 2: disease is the baseline requirement. It obviously has to work right,
• 8:29
  Speaker 2: but commercial success in clinical success over the long term
• 8:34
  Speaker 2: is heavily dependent on tolerability. Think about the doctor's perspective. Okay,
• 8:38
  Speaker 2: a psychiatrist's loyalty to prescribing a specific brand isn't just
• 8:43
  Speaker 2: about the elegance of the chemical formula. Their loyalty is
• 8:47
  Speaker 2: totally tethered to their patient's willingness to stick with the
• 8:50
  Speaker 2: treatment plan.
• 8:50
  Speaker 1: Because if the patient stops taking it, the treatment fails.
• 8:53
  Speaker 2: Exactly, if a specific drug causes a patient to abandon
• 8:57
  Speaker 2: their treatment and end up back in the hospital, doctor
• 9:00
  Speaker 2: will abandon that drug.
• 9:01
  Speaker 1: So when we talk about a microscopic chemical modulation, that
• 9:04
  Speaker 1: partial atomus mechanism acting like a smart valve, we are
• 9:07
  Speaker 1: actually talking about a mechanism that dictates human behavior.
• 9:11
  Speaker 2: It keeps the patient compliant, right.
• 9:12
  Speaker 1: Which keeps the doctor prescribing it, which keeps a franchise
• 9:15
  Speaker 1: partner in business.
• 9:17
  Speaker 2: It is the foundation of the entire revenue stream.
• 9:20
  Speaker 1: But wait, this assumes the patient is operating with a
• 9:23
  Speaker 1: baseline level of cooperation, right Like, Okay, the plumbing is fixed,
• 9:27
  Speaker 1: the side effects are minimal. But what happens if the
• 9:30
  Speaker 1: homeowner is actively barricading the front door and won't let
• 9:33
  Speaker 1: the plumber inside to begin.
• 9:35
  Speaker 2: With, That is a very real scenario.
• 9:37
  Speaker 1: Because I'm struggling to see how a lack of side
• 9:40
  Speaker 1: effect solves the problem. If you are dealing with a
• 9:43
  Speaker 1: patient who's very condition like severe paranoia in schizophrenia or
• 9:47
  Speaker 1: a manic episode, makes them inherently suspicious or physically resistant
• 9:51
  Speaker 1: to taking a pill in the first place.
• 9:53
  Speaker 2: Right, the paranoia overrides the logic exactly.
• 9:56
  Speaker 1: It doesn't matter how few side effects the drug has
• 9:59
  Speaker 1: if the patient's illness is actively telling them that the
• 10:02
  Speaker 1: pill is poison.
• 10:03
  Speaker 2: And that is the secondary hurdle, and it requires a
• 10:05
  Speaker 2: completely different type of innovation. You solve the chemical problem
• 10:09
  Speaker 2: of side effects with the partial agonist, but now you
• 10:12
  Speaker 2: have a mechanical problem.
• 10:14
  Speaker 1: A mechanical problem, Yes, how.
• 10:16
  Speaker 2: Do you ensure the drug actually gets into the system
• 10:19
  Speaker 2: of a patient who might be actively resisting it?
• 10:21
  Speaker 1: I mean, if they are that paranoid, wouldn't they just
• 10:23
  Speaker 1: refuse to open their mouths?
• 10:24
  Speaker 2: Sometimes? Yes, But in a psychiatric ward or an outpatient
• 10:28
  Speaker 2: care setting, outright physical refusal is actually less common than
• 10:34
  Speaker 2: the performance of compliance.
• 10:36
  Speaker 1: The performance of compliance, what does that mean?
• 10:38
  Speaker 2: Well, patients with severe schizophrenia or bipolar disorder often struggle
• 10:43
  Speaker 2: to swallow conventional tablets, either due to physical difficulty or
• 10:48
  Speaker 2: just profound psychological resistance. So a very common daily hurdle
• 10:53
  Speaker 2: in psychiatric care is a patient pretending to take the medication.
• 10:56
  Speaker 1: Oh, the sources refer to this, They call it cheeking.
• 10:59
  Speaker 2: Right, Cheeking is a massive issue. A patient will take
• 11:02
  Speaker 2: the conventional tablet, put it in their mouth, take a
• 11:06
  Speaker 2: sip of water, and subtly hide the hard pill under
• 11:09
  Speaker 2: their tongue or tuck deep in their cheek.
• 11:11
  Speaker 1: Wow, so they don't swallow it at all.
• 11:12
  Speaker 2: Right, They swallow the water, open their mouth briefly to
• 11:15
  Speaker 2: show the nurse, and then the moment the caregiver turns around,
• 11:18
  Speaker 2: they spit the pill into the trash.
• 11:19
  Speaker 1: Which forces nurses to do these invasive, tense standoffs where
• 11:23
  Speaker 1: they have to like make the patient lift their tongue,
• 11:25
  Speaker 1: pull back their cheeks, and definitively prove they swallowed it exactly.
• 11:29
  Speaker 2: It creates an incredibly adversarial relationship between the patient and
• 11:33
  Speaker 2: the caregiver. It is stressful, it's time consuming, and often
• 11:37
  Speaker 2: patients are still clever enough to hide the medication anyway.
• 11:40
  Speaker 1: And that brings us to the delivery system. The mechanical
• 11:43
  Speaker 1: solution highlighted in our stack of notes, and here's where
• 11:46
  Speaker 1: it gets really interesting.
• 11:48
  Speaker 2: It really does.
• 11:49
  Speaker 1: The sources focus on a very specific product in the
• 11:52
  Speaker 1: Indian market. It's called Ericure ten MD and it's manufactured
• 11:58
  Speaker 1: by Holy Evolution Pharma. Ten milligram airpipperzole formulation.
• 12:02
  Speaker 2: With the MD is the crucial part there.
• 12:04
  Speaker 1: Yes, it stands for mouth dissolving. This is a tablet
• 12:08
  Speaker 1: that dissolves instantly on the tongue without needing a single
• 12:11
  Speaker 1: drop of water.
• 12:12
  Speaker 2: And to an everyday consumer, you know, a mouth dissolving
• 12:15
  Speaker 2: tablet might just seem like a neat convenience.
• 12:17
  Speaker 1: Yeah, like for cold medicine or something, right.
• 12:19
  Speaker 2: Maybe you have a sore throat or you just don't
• 12:21
  Speaker 2: have a glass water handy in the car. But for
• 12:23
  Speaker 2: a psychiatrist or a psychiatric nurse managing difficult, uncooperative or
• 12:28
  Speaker 2: highly paranoid patients, this format fundamentally shifts the power dynamic
• 12:33
  Speaker 2: of administration.
• 12:34
  Speaker 1: It's a game changer.
• 12:35
  Speaker 2: It really is a critical clinical tool. It's a clinically
• 12:39
  Speaker 2: meaningful difference, not just a preference.
• 12:41
  Speaker 1: It's essentially a reverse magic trick. Think about what a
• 12:45
  Speaker 1: magician does. Their whole goal is to make a solid
• 12:48
  Speaker 1: object like a coin, disappear by hiding it. They slip
• 12:52
  Speaker 1: it up a sleeve or palmt so you can't see
• 12:54
  Speaker 1: it right, but the eric you're ten MD tablet is
• 12:56
  Speaker 1: engineered to disappear instantly, precisely so it cannot be hidden.
• 13:01
  Speaker 1: The moment that pill touches the natural moisture of the
• 13:03
  Speaker 1: human tongue, it breaks down. It just vanishes into the
• 13:06
  Speaker 1: patient's system exactly. By dissolving instantly, it completely eliminates the
• 13:11
  Speaker 1: mechanical ability of the patient to cheek it.
• 13:13
  Speaker 2: You are bypassing the behavioral resistance through physical engineering. The
• 13:18
  Speaker 2: instant dissolve feature ensures that the medication is delivered immediately.
• 13:22
  Speaker 1: Even if they don't want it to be exactly.
• 13:24
  Speaker 2: Even if the patient takes the pill and their immediate
• 13:26
  Speaker 2: impulse a split second later is to try and spit
• 13:29
  Speaker 2: it out, they can't.
• 13:30
  Speaker 1: It's too late.
• 13:30
  Speaker 2: By the time they react, the tablet has already turned
• 13:33
  Speaker 2: into a liquid and absorbed through the mucosal lining of the.
• 13:36
  Speaker 1: Mouth, So you've taken the friction completely out of the equation.
• 13:40
  Speaker 1: The nurse doesn't need to fetch water, they don't need
• 13:43
  Speaker 1: to coach the patient to swallow, and they definitely don't
• 13:45
  Speaker 1: need to do a five minute cheek inspection afterward.
• 13:48
  Speaker 2: The disappearing act guarantees the medicine was administered.
• 13:52
  Speaker 1: And when you remove that friction for the caregiver and
• 13:55
  Speaker 1: the doctor, you create immense brand loyalty, which I think
• 14:00
  Speaker 1: brings us back to the business side of things, right.
• 14:02
  Speaker 1: It does specifically that PCD franchise model we started with,
• 14:06
  Speaker 1: because when you are a franchise partner in India, you
• 14:09
  Speaker 1: aren't just selling a raw molecule. No.
• 14:12
  Speaker 2: If we connect this to the bigger picture, you are
• 14:15
  Speaker 2: selling a highly engineered solution to a psychiatrist's most annoying
• 14:18
  Speaker 2: daily problem. Yeah, look at the sheer volume of the
• 14:22
  Speaker 2: Indian pharmaceutical landscape. Is one of the largest manufacturers of
• 14:26
  Speaker 2: generic drugs in the world. It's massive, So a doctor
• 14:29
  Speaker 2: has dozens, maybe hundreds of different generic options for prescribing
• 14:34
  Speaker 2: arapit prozole. If the doctor just scribbles arapit presole ten
• 14:38
  Speaker 2: milligrams on the prescription pad, the pharmacists will fill it
• 14:41
  Speaker 2: with whatever generic brand they happen to have in stock.
• 14:43
  Speaker 1: But the standard generic brand is a hard tablet, which
• 14:47
  Speaker 1: means the patient can cheek it and spit it.
• 14:49
  Speaker 2: Out exactly, which is exactly why the doctor changes their
• 14:52
  Speaker 2: behavior to guarantee the patient actually ingests the medicine, the
• 14:56
  Speaker 2: doctor must write a prescription for the specific mouth dissolving.
• 14:59
  Speaker 1: Formulation, so they have to write Ericure ten MD. Yes,
• 15:03
  Speaker 1: let's trace this economic loop because this is where the
• 15:05
  Speaker 1: franchise monopoly actually clicks into place. Holy Evolution Pharma manufactures
• 15:10
  Speaker 1: this highly specialized eric Cure ten MD formulation, and our
• 15:13
  Speaker 1: sources point out they do this in who GMP certified facilities.
• 15:18
  Speaker 2: Right World Health Organization Good Manufacturing Practices. That certification is
• 15:22
  Speaker 2: the gold standard.
• 15:23
  Speaker 1: That's a big deal.
• 15:24
  Speaker 2: It is in a market totally flooded with generics of
• 15:27
  Speaker 2: varying quality. WHOGMP certification guarantees consistency and safety. It tells
• 15:33
  Speaker 2: the doctor that every single dissolving tablet will perform exactly
• 15:36
  Speaker 2: as expected.
• 15:37
  Speaker 1: Okay, So Holy Evolution Pharma provides this top tier product,
• 15:42
  Speaker 1: and then they grant a local franchise partner the monopoly
• 15:45
  Speaker 1: rights for a specific territory, meaning in that city or region,
• 15:50
  Speaker 1: this one business owner is the sole exclusive distributor of
• 15:54
  Speaker 1: eric Cure ten MD.
• 15:56
  Speaker 2: Right. Now, follow the chain of incentives here. Okay, the
• 15:59
  Speaker 2: psychiatrist prescribes this specific NB tablet because the instant dissolving
• 16:04
  Speaker 2: format guarantees patient compliance at the exact moment of administration.
• 16:09
  Speaker 2: They know the patient can't hide it, right.
• 16:11
  Speaker 1: And then the patient actually stays on the medication long
• 16:14
  Speaker 1: term because the partial agonist mechanism, you know, the smart valve,
• 16:17
  Speaker 1: means they aren't suffering from severe weight gain or heavy sedation.
• 16:20
  Speaker 2: They tolerate it well enough to just live their lives. Yeah,
• 16:23
  Speaker 2: and because the patient is stable and compliant, the doctor
• 16:26
  Speaker 2: keeps writing the prescription for that exact brand month after month.
• 16:29
  Speaker 1: And because the local franchise partner has monopoly rights in
• 16:32
  Speaker 1: their territory, they capture one hundred percent of that revenue.
• 16:36
  Speaker 1: They secure a long term, highly predictable, repeat prescription relationship
• 16:40
  Speaker 1: with that doctor.
• 16:41
  Speaker 2: It creates this completely self sustaining loop where the patient
• 16:44
  Speaker 2: stays compliant and the doctor, the doctor just keeps prescribing
• 16:48
  Speaker 2: it month after month exactly because they trust the outcome.
• 16:51
  Speaker 1: So what does this all mean. It is a perfect
• 16:54
  Speaker 1: self sustaining economic loop. Like we started this deep dive
• 16:58
  Speaker 1: talking about how massive business empires are built, and we
• 17:01
  Speaker 1: usually look for skyscrapers, but here we have a highly lucrative,
• 17:06
  Speaker 1: nationwide monopoly rights business model resting entirely on the ability
• 17:11
  Speaker 1: of a single tablet to dissolve fast enough to outpace
• 17:14
  Speaker 1: a psychiatric patient's hesitation.
• 17:16
  Speaker 2: It's incredible. It really shows you that in the pharmaceutical industry,
• 17:19
  Speaker 2: financial success isn't just about having a drug that technically
• 17:23
  Speaker 2: works in a petri dish.
• 17:24
  Speaker 1: It's way more complex than that.
• 17:25
  Speaker 2: It is about understanding every single point of behavioral and
• 17:29
  Speaker 2: biological friction between that drug and the human being who
• 17:32
  Speaker 2: actually has to take it, and then systematically engineering those
• 17:35
  Speaker 2: friction points out of existence.
• 17:37
  Speaker 1: Which is just an incredible journey to trace. We started
• 17:41
  Speaker 1: all the way down at the microscopic level, looking at
• 17:43
  Speaker 1: how a partial agonist modulates a dopamine receptor like a
• 17:47
  Speaker 1: firmistat instead of shutting it down completely, and then we
• 17:50
  Speaker 1: moved up to the human element, seeing how that chemical
• 17:53
  Speaker 1: modulation saves a patient from zombification, basically making them willing
• 17:57
  Speaker 1: to stay on their meds.
• 17:58
  Speaker 2: The tolerability factor.
• 18:01
  Speaker 1: From there, we looked at the physical delivery the Ercure
• 18:04
  Speaker 1: ten MD tablet serving as a reverse magic trick to
• 18:07
  Speaker 1: bypass psychological resistance on the ward, and finally we saw
• 18:11
  Speaker 1: how all of that friction free engineering creates a bulletproof
• 18:15
  Speaker 1: repeat prescription franchise business model.
• 18:18
  Speaker 2: It perfectly illustrates that biology, psychology, and economics do not
• 18:22
  Speaker 2: exist in silos. They're connected. You cannot succeed the macroeconomics
• 18:26
  Speaker 2: without mastering the human psychology, and you cannot master the
• 18:30
  Speaker 2: psychology without fine tuning the microscopic biology.
• 18:33
  Speaker 1: It's all tied together. But looking at this incredible feed
• 18:36
  Speaker 1: of engineering, it does leave us with the fascinating and
• 18:39
  Speaker 1: maybe slightly unsettling question about the future.
• 18:42
  Speaker 2: It does. We have seen how effectively this instant dissolve
• 18:45
  Speaker 2: format overrides a patient's hesitation. Right, it is at its
• 18:50
  Speaker 2: core compliance engineering.
• 18:52
  Speaker 1: Yeah, that's exactly what it is.
• 18:53
  Speaker 2: It is designed to ensure consumption regardless of the consumer's
• 18:57
  Speaker 2: immediate impulse to reject it. Now, in psychiatry, that is
• 19:00
  Speaker 2: a life saving clinical tool.
• 19:01
  Speaker 1: It's necessary, for sure.
• 19:03
  Speaker 2: But if delivery formats are being explicitly designed to bypass
• 19:07
  Speaker 2: human reluctance, how long until we see this kind of
• 19:11
  Speaker 2: compliance engineering pushed into everyday consumer wellness, diet supplements, or
• 19:15
  Speaker 2: even our food.
• 19:16
  Speaker 1: Oh man, if a company figures out how to make
• 19:18
  Speaker 1: a supplement or an energy booster dissolve instantly on your
• 19:21
  Speaker 1: tongue before you can second guess the taste or the texture.
• 19:24
  Speaker 1: They absolutely will right.
• 19:25
  Speaker 2: So are we moving toward a future where what we
• 19:28
  Speaker 2: consume is physically engineered to bypass our own hesitation, where
• 19:32
  Speaker 2: it fundamentally changes our relationship with personal agency and what
• 19:35
  Speaker 2: we actually allow into our bodies.
• 19:37
  Speaker 1: That's wild. From building microscopic empires in a neuropharma franchise
• 19:41
  Speaker 1: to questioning the future of human agency and consumer compliance,
• 19:45
  Speaker 1: it really all starts with one tiny dissolving molecule. We
• 19:49
  Speaker 1: will leave you to ponder that for yourself, Keep questioning,
• 19:51
  Speaker 1: keep learning, and we will see you on the next
• 19:53
  Speaker 1: deep dive.